Androgen Receptor in Human Health: A Potential Therapeutic Target

    December 2012 in “ Current Drug Targets
    Hifzur R. Siddique, Sanjiv Nanda, Aijaz Parray, Mohammad Saleem
    Image of study
    TLDR The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.
    The document from 2012 reviews the role of the Androgen Receptor (AR) in various diseases, including cancer, and explores the potential of AR as a therapeutic target. It details AR's involvement in diseases like prostate and breast cancer, androgenetic alopecia, and polycystic ovary syndrome. The review discusses both natural and synthetic compounds that inhibit AR signaling, such as Lupeol, genistein, and the synthetic agents bicalutamide and MDV3100, the latter showing promise in early clinical trials. It also covers natural agents like quercetin and curcumin, which modulate AR activity and could serve as therapeutic agents. The document emphasizes the need for further studies to confirm the efficacy of these agents as AR antagonists and to determine appropriate dosages and treatment durations. The authors note the non-toxic nature of many natural compounds and the importance of considering interspecies differences when extrapolating results from animal studies to humans.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results

    Related Community Posts Join

    6 / 1000+ results

      community A Technical Question About Pyrilutamide

      in Research/Science  5 upvotes 1 year ago
      Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  136 upvotes 7 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community Androgenetic alopecia is a skin disease: DHT-mediated skin disorders

      in Research/Science  65 upvotes 1 year ago
      Dihydrotestosterone (DHT) impacts various skin conditions, including Androgenetic alopecia and seborrheic dermatitis, by causing overactivity in sebaceous glands. Topical medications Tacrolimus and Clobetasol can reduce these inflammatory conditions, and treatments like RU58841, Minoxidil, and Finasteride may also be beneficial.

    Similar Research

    5 / 1000+ results